Cetylpyridinium chloride monohydrate en es it fr

Cetylpyridinium chloride monohydrate Brand names, Cetylpyridinium chloride monohydrate Analogs

Cetylpyridinium chloride monohydrate Brand Names Mixture

  • No information avaliable

Cetylpyridinium chloride monohydrate Chemical_Formula

No information avaliable

Cetylpyridinium chloride monohydrate RX_link

http://www.rxlist.com/cgi/generic2/cetrorelix.htm

Cetylpyridinium chloride monohydrate fda sheet

Cetylpyridinium_chloride_monohydrate FDA

Cetylpyridinium chloride monohydrate msds (material safety sheet)

Cetylpyridinium chloride monohydrate Synthesis Reference

No information avaliable

Cetylpyridinium chloride monohydrate Molecular Weight

1431.06 g/mol

Cetylpyridinium chloride monohydrate Melting Point

No information avaliable

Cetylpyridinium chloride monohydrate H2O Solubility

No information avaliable

Cetylpyridinium chloride monohydrate State

Solid

Cetylpyridinium chloride monohydrate LogP

No information avaliable

Cetylpyridinium chloride monohydrate Dosage Forms

Powder for solution

Cetylpyridinium chloride monohydrate Indication

For the inhibition of premature LH surges in women undergoing controlled ovarian stimulation.

Cetylpyridinium chloride monohydrate Pharmacology

Cetrorelix is a synthetic decapeptide with gonadotropin-releasing hormone (GnRH) antagonistic activity. GnRH induces the production and release of luteinizing hormone (LH) and follicle stimulating hormone (FSH) from the gonadotrophic cells of the anterior pituitary. Due to a positive estradiol (E2) feedback at midcycle, GnRH liberation is enhanced resulting in an LH-surge. This LH-surge induces the ovulation of the dominant follicle, resumption of oocyte meiosis and subsequently luteinization as indicated by rising progesterone levels. Cetrorelix competes with natural GnRH for binding to membrane receptors on pituitary cells and thus controls the release of LH and FSH in a dose-dependent manner.

Cetylpyridinium chloride monohydrate Absorption

Rapidly absorbed following subcutaneous injection. The mean absolute bioavailability following subcutaneous administration to healthy female subjects is 85%.

Cetylpyridinium chloride monohydrate side effects and Toxicity

No information avaliable

Cetylpyridinium chloride monohydrate Patient Information

Cetylpyridinium chloride monohydrate Organisms Affected

Humans and other mammals